CROs offering Discovery Research with Cell Therapy
16 published
16 published CROs match Discovery Research and Cell Therapy.
Locations in this set include United States, China, India, United Kingdom, 30 countries, and 30+ countries.
Capabilities that show up most often in this set: Preclinical In Vitro Studies, Translational Research, In Vivo Efficacy Models, In Vivo PK / PD Studies, and Preclinical In Vivo Studies.
Matching companies
Aragen Life SciencesGlobal CRDMO partner offering integrated discovery-to-commercialization services across small molecules and biologics, with 4000+ scientists and R&D/manufacturing campuses in Asia, North America, and Europe.
Avigen LtdAvigen offers avidity-based profiling of live immune–target cell interactions for immunotherapy discovery and preclinical validation. Its platform supports TCR-T, CAR-T, and NK programmes across solid tumour indications.
CertaraCertara transforms drug development with proprietary biosimulation software, predictive modeling, and AI-driven services spanning discovery through commercialization. Serving 2,400+ biopharmaceutical companies and regulatory agencies across 70 countries, Certara's model-informed drug development (MIDD) platform accelerates clinical and regulatory decision-making.
Crown BiosciencePreclinical oncology CRO offering 2,500+ PDX models, organoid and cell line databases, and translational platforms with biomarker discovery and AI-driven systems biology for drug development.
Cyagen BiosciencesCyagen provides genetically engineered animal models, custom cell lines, and viral packaging services for preclinical research, with specialized expertise in humanized mice, gene therapy vectors, and disease-specific models across oncology, neurology, and metabolic disorders.
Frontage LaboratoriesGlobal pharmaceutical development organization offering integrated drug discovery, preclinical safety/toxicology, DMPK, bioanalytical, and clinical trial services across 28 sites with 2,200 employees and 200+ FDA inspections.
IPM BiotechIPM Biotech (生创精准医疗科技有限公司) is a cell technology and regenerative medicine company founded in 2015 by a team of renowned returnee scientists specializing in stem cells and regenerative medicine.
KCAS BioLeading bioanalytical CRO with 45+ years of experience, supporting 315+ approved drugs through bioanalysis, biomarker, immunogenicity, flow cytometry, and clinical kitting services across US, EU, and Australia facilities.
Noble Life SciencesAdvanced preclinical CRO providing comprehensive drug and device development services including bioanalysis, GLP toxicology, pharmacodynamic modeling, and specialized testing for oncology, infectious disease, gene therapy, and synthetic biology programs.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
Proone LabsProone Labs provides preclinical pharmacology, drug discovery, and regulatory support services to biotech startups, traditional pharma, and in-silico companies. The team has delivered 30+ assays, 50+ cell lines, and supported 4 FDA drug approvals across multiple therapeutic areas.
ProtheragenSpecialized preclinical CRO dedicated to obesity research, offering comprehensive animal models, pharmacokinetic/pharmacodynamic studies, bioanalysis, and safety assessment for anti-obesity drug development.
Reaction BiologyGlobal preclinical CRO specializing in kinase drug discovery, cell-based assays, in vivo pharmacology, and immuno-oncology with 1,000+ cell lines and hundreds of validated protein targets across US and EU facilities.
STEMCELL Technologies Inc.STEMCELL Technologies develops and sells cell culture media, cell separation systems, instruments, and reagents for life sciences research, plus contract research services including biopharmaceutical testing, cell characterization, toxicity testing, and organoid assays.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
WuXi AppTecGlobal CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Markdown mirror: /explore/discovery-research/cell-therapy.md